Recent Updates
Recently added Catalysts
IMVT Positive Sentiment

Immunovant to Host Conference Call and Webcast to Report Initial IMVT-1402 Phase 1 Results on September 26, 2023

Tuesday, September 26, 2023 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Immunovant, Inc. announced it will report initial results from the Phase 1 trial of IMVT-1402 on September 26, 2023. Following the results, a conference call and webcast will be held at 8:00 a.m. ET for discussion. The company is recognized for its commitment to developing targeted therapies for autoimmune diseases, utilizing anti-FcRn technology. This reflects ongoing efforts to address complex healthcare needs in the spectrum of autoimmune disorders.
Price reaction · baseline $20.28 (2023-09-25 close) · hit after-hours · 1 other IMVT headline(s) in the window, move may be shared
day 0 close · peak
+97%
day 1
+94.8%
day 3
+89.3%

Market Sentiment Analysis

POSITIVE FACTORS

  • Immunovant is set to report initial Phase 1 results, indicating progress.
  • The company is focused on innovative therapies for autoimmune diseases.
  • The announcement of the conference call highlights transparency and communication with investors.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+85%
120-day peak, hindsight
Typical move
7.3%
average across 5 past catalysts
Cash runway
~19 mo
Low dilution risk
Lead asset
IMVT-1402
Phase 3 · Generalized Myasthenia Gravis

Full Press Release Details

NEW YORK, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that it will report initial IMVT-1402 Phase 1 results on Tuesday, September 26, 2023. Following the announcement, the Company will host a conference call and webcast at 8:00 a.m. ET to discuss the results.
To participate in the conference call, please register in advance here. To access the live and archived webcast, please visit Immunovant’s website at https://www.immunovant.com/investors/news-events. The archived webcast will be available for a limited time on the Company’s website.
About Immunovant, Inc.
Immunovant, Inc. is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-FcRn technology, the Company is developing innovative, targeted therapies to meet the complex and variable needs of people with autoimmune diseases. For additional information on the Company, please visit www.immunovant.com.
Chau Cheng, PhD, MBA

Frequently Asked Questions

When will Immunovant report IMVT-1402 Phase 1 results?

Immunovant will report the initial IMVT-1402 Phase 1 results on September 26, 2023.

What time is the conference call for IMVT-1402 results?

The conference call will be held at 8:00 a.m. ET on September 26, 2023.

How can I access the IMVT-1402 webcast?

You can access the live and archived webcast on Immunovant's website.

What is Immunovant's focus area?

Immunovant focuses on developing therapies for autoimmune diseases.

Who is the VP of Investor Relations at Immunovant?

Chau Cheng, PhD, MBA, is the VP of Investor Relations at Immunovant.

ShareAdd on Google
Tags: IMVT Viatris Investor Conferences Healthcare Immunovant IMVT-1402 Phase 1 results autoimmune diseases clinical-stage
Last updated: Sep 26, 2023

Biotech snapshot

Cash runway
$798M liquidity · $41M/mo burn
~19 mo
Low dilution risk
Lead asset
IMVT-1402Phase 3
Generalized Myasthenia Gravis →

Catalyst track record

+85%
best trade around IMVT's most recent catalyst

Peak hindsight return over a 120-day window, across 5 tracked FDA/PDUFA catalysts for IMVT.

See every catalyst's timing & PoA →